Clinical stage AI drug discovery company, MindRank, has announced the start of its first-in-human (FIH) Phase 1 study of MDR-001 in China. The proprietary glucagon-like peptide 1 receptor agonist (GLP-1 RA), which is an oral small-molecule designed to treat obesity and type 2 diabetes mellitus (T2DM), was discovered using MindRank's Molecule Pro AI platform. The FIH Phase 1 trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of MDR-001 in healthy volunteers and patients with obesity or T2DM.
MindRank CEO Zhangming Niu said that the initiation of their clinical trial with MDR-001 is a significant milestone for the company and a validation of their AI platform's potential. The company plans to advance the clinical development of MDR-001 globally to make it available as soon as possible.
The randomized, double-blind, placebo-controlled, dose-escalation FIH Phase 1 study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of MDR